Search
Flizasertib
go.drugbank.com/drugs/DB21613InvestigationalFlizasertib has a monoisotopic molecular weight of 271.11 Da. … Flizasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Flizasertib is a serine/threonine kinase inhibitor.
ND7001
go.drugbank.com/drugs/DB05142ExperimentalND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. … Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity.
Lotiglipron
go.drugbank.com/drugs/DB21631InvestigationalLotiglipron has a monoisotopic molecular weight of 574.2 Da. … Lotiglipron is a small molecule drug. The usage of the INN stem '-glipron' in the name indicates that Lotiglipron is a glucagon-like peptide 1 receptor (GLPIR) agonist.
Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
go.drugbank.com/drugs/DB16709Approved[L35525] Stratagraft consists of two kinds of lab-grown skin cells, keratinocytes and dermal fibroblasts, which are grown together on a murine collagen matrix to make a bi-layered construct (i.e. a … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigational, and a high level of accumulation in tumors. … Unlike <sup>68</sup>Ga-labeled PSMA-targeting ligands, <sup>18</sup>F-labeled compounds targeting this protein have a longer half-life and can be produced in larger batches.
Eliapixant
go.drugbank.com/drugs/DB21465InvestigationalEliapixant has a monoisotopic molecular weight of 478.13 Da. … Eliapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Mivebresib
go.drugbank.com/drugs/DB21300InvestigationalMivebresib has a monoisotopic molecular weight of 459.11 Da. … Mivebresib is a small molecule drug.
AVR-RD-02
go.drugbank.com/drugs/DB17650InvestigationalIt consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified _ex vivo_ with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that,
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalBamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … [A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells.